Opthea : Quarterly Activity Report - Form 6-K

Quarterly Activity Report


Q3 FY24


Highlights


•

Completion of enrolment in first trial of sozinibercept's Phase 3 pivotal program...

Related Keywords

United States ,American ,Julie Clark ,Xand Linkedin ,Arshad Khanani ,Silvana Guerci Lena ,Arshadm Khanani ,Fred Guerard ,Astellas Company ,Genentech United States Inc ,Fellowship At Sierra Eye Associates ,Exchange Commission ,Leadership Team ,University Of Nevada ,Clinical Development ,Drug Administration ,Nasdaq ,Lomb Corporation ,Reno School Of Medicine ,Exchange Commission On ,Sierra Eye Associates ,Development Funding Agreement ,Clinical Research ,Roche Group ,Regulatory Affairs ,Alcon Inc ,Opthea Limited ,Quarterly Activity Report ,Chief Medical Advisor ,Quarterly Activityreport ,Chief Executive Officer ,Fast Track Designation ,Senior Vice President ,Managing Partner ,Clinical Associate Professor ,Reno School ,United State ,Vice President Clinical Development ,Any Future Capital Raise ,Non Executive Directors ,Genentech United States ,Risk Factors ,Half Year Report ,American Depositary ,Securities Litigation Reform Act ,Annual Report ,Year Report ,Listing Rule ,Paidfor Directors ,Markets ,